# Nicolas A Giraldo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5961814/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 31<br>papers | 6,324<br>citations | 236833<br>25<br>h-index | 477173<br>29<br>g-index |
| 32<br>all docs | 32<br>docs citations | 32<br>times ranked | 9718<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Estimating theÂpopulation abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biology, 2016, 17, 218. | 3.8 | 1,980 |
| 2 | Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clinical Cancer Research, 2016, 22, 4057-4066. | 3.2 | 433 |
| 3 | Tertiary lymphoid structures in cancer and beyond. Trends in Immunology, 2014, 35, 571-580. | 2.9 | 418 |
| 4 | The clinical role of the TME in solid cancer. British Journal of Cancer, 2019, 120, 45-53. | 2.9 | 380 |
| 5 | Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. Clinical Cancer Research, 2015, 21, 3031-3040. | 3.2 | 355 |
| 6 | Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology, 2018, 31, 214-234. | 2.9 | 278 |
| 7 | Tertiary lymphoid structures, drivers of the antiâ€tumor responses in human cancers. Immunological Reviews, 2016, 271, 260-275. | 2.8 | 277 |
| 8 | Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 4416-4428. | 3.2 | 252 |
| 9 | Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting. Clinical Cancer Research, 2015, 21, 1329-1339. | 3.2 | 250 |
| 10 | Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. Frontiers in Immunology, 2016, 7, 407. | 2.2 | 238 |
| 11 | Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Advances in Immunology, 2016, 130, 95-190. | 1.1 | 160 |
| 12 | Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. Cancer Immunology Research, 2019, 7, 1091-1105. | 1.6 | 153 |
| 13 | The immune contexture of primary and metastatic human tumours. Current Opinion in Immunology, 2014, 27, 8-15. | 2.4 | 137 |
| 14 | Cancer immune contexture and immunotherapy. Current Opinion in Immunology, 2016, 39, 7-13. | 2.4 | 132 |
| 15 | Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. , 2018, 6, 99. | | 129 |
| 16 | Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade. Science, 2021, 372, . | 6.0 | 114 |
| 17 | Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. Cancer Immunology, Immunotherapy, 2018, 67, 981-988. | 2.0 | 89 |
| 18 | The Immune Microenvironment: A Major Player in Human Cancers. International Archives of Allergy and Immunology, 2014, 164, 13-26. | 0.9 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Association of IL-36Î³ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. Cancer Immunology, Immunotherapy, 2019, 68, 109-120. | 2.0 | 59 |
| 20 | Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). OncoImmunology, 2015, 4, e1049804. | 2.1 | 51 |
| 21 | The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 127-135. | 1.4 | 51 |
| 22 | Increased CD4+/CD8+ Double-Positive T Cells in Chronic Chagasic Patients. PLoS Neglected Tropical Diseases, 2011, 5, e1294. | 1.3 | 50 |
| 23 | T Lymphocytes from Chagasic Patients Are Activated but Lack Proliferative Capacity and Down-Regulate CD28 and CD3Î¶. PLoS Neglected Tropical Diseases, 2013, 7, e2038. | 1.3 | 31 |
| 24 | Shaping of an effective immune microenvironment to and by cancer cells. Cancer Immunology, Immunotherapy, 2014, 63, 991-997. | 2.0 | 30 |
| 25 | Immune-based identification of cancer patients at high risk of progression. Current Opinion in Immunology, 2018, 51, 97-102. | 2.4 | 29 |
| 26 | Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Reports, 2021, 36, 109599. | 2.9 | 27 |
| 27 | Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 463-474. | 1.4 | 16 |
| 28 | T cells responding to Trypanosoma cruzi detected by membrane TNFâ€Î± and CD154 in chagasic patients. Immunity, Inflammation and Disease, 2018, 6, 47-57. | 1.3 | 11 |
| 29 | Spatial UMAP and Image Cytometry for Topographic Immuno-oncology Biomarker Discovery. Cancer Immunology Research, 2021, 9, 1262-1269. | 1.6 | 8 |
| 30 | The Human Tumor Microenvironment. , 2018, , 5-21. | | 2 |
| 31 | PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385. | | 2 |